Ben Miron

@apolo_andrea @Uromigos @tompowles1 @brian_rini @alantanmd @DrChoueiri @bergsa83 @DrRosenbergMSK @HHammersMD @DrRanaMcKay @TDorffOnc Uber Platinum

So excited to be in Nashville for the #UromigosLive24 🚨 @Uromigos with @tompowles1, @brian_rini and all our #GU super ⭐️ colleagues. Got the warmest welcome and coolest airport pickup by @alantanmd!

💡Will #ctDNA serve as a treatment response biomarker in metastatic cancers? Here’s a thorough evaluation in @CCR_AACR from the RECIST working group, looking at the next steps towards using ctDNA for novel early endpoints in clinical trials and beyond. 👉 doi.org/10.1158/1078-0…

📢Close fup, limited censoring shows true OS durability in this small vanguard cohort of met #bladdercancer pts rx w EVP. Particularly impressive in cis inelig who often have comorbidities. Kudos to teams that invest in/prioritize long term follow up of metastatic trials! #ESMO24

@DrChoueiri @Dr_Aggen @OncoAlert @urotoday @OncLive @DrYukselUrun @FabioSchutz78 @oncodaily @OncoBellmunt @tompowles1 @KarlSemaan @SylvanBacaLab @marc_eid Exciting to see new (methylation) based approaches with this sort of data!

Liquid biopsy is here to stay! Clearance of ctDNA in neoadjuvant phase is associated with improved outcomes to durva + tremlo + EV in cis-ineligible pts with MIBC # ESMO24 @OncoAlert

@_backtableUro @kategessner_uro @uretericbud @TempleUrology @drphil_urology @angiesmith_uro @UroDoco @betsykoehne @NityaAbraham Great insights for all careers in medicine/ adjacent fields!

This week, @uretericbud @TempleUrology shares insights on developing a sustainable and fulfilling career as a urologic surgeon @drphil_urology @angiesmith_uro @urodoco @betsykoehne @nityaabraham #URO181 open.spotify.com/episode/7MqCHd…

TP53: - Discovered 45 years ago, most cited gene all time - No therapies - 500 million people currently living will die of TP53 mutant cancers without new therapies Our Preprint: - A general strategy for TP53 missense mutant cancers (majority) with prototype small molecules

@LaurenMachos Congrats Lauren!

@PBarataMD @JasonBrownMDPhD @UHhospitals @GUONCGarciaJA @TedTeknosMD @PrateekMendira3 @angela_jia_ @caseccc @neerajaiims @brian_rini @KimAllman4 @PGrivasMDPhD @montypal @LPonsky Congrats @PBarataMD !!

@JasonBrownMDPhD @UHhospitals @GUONCGarciaJA @TedTeknosMD Thank you @JasonBrownMDPhD !! Such a special evening celebrating the infinite generosity and kindness of #Miggofamily supporting our mission to advance #GU cancer research at @UHhospitals @GUONCGarciaJA @PrateekMendira3 @angela_jia_ @caseccc

Congratulations to @PBarataMD for being named the Miggo family chair in cancer research @UHhospitals! Well earned honor and inspiring story

Hundreds of Jewish students at @Columbia just published one of the most incredible student letters I have ever read. It's not only magnificently written, but it also clearly articulates their experiences on campus for the past six months. Their letter tells the story of what's it like being a Jewish student right now better than any professor like myself could ever do. Please take 4-5 minutes to read their letter. Give Jewish students a voice. docs.google.com/document/u/1/d…

A lot about anti-NECTIN4 ADC Enfortumab vedotin (EV) beyond UC at #ASCO24! @ASCO Data of multi-cohort EV-202 (NCT04225117) will be released! ➡️Excited to see the single-agent activity of EV in biomarker-unselected (NECTIN4 status not required!) - gastric/esophageal cancer (Abstract # 4046) - NSCLC (Abstract # 8585) - TNBC & HR+/HER2- breast cancer (Abstract # 1005) ➡️Our recent data highlights the correlation between NECTIN4 targetability and EV response, which is consistent with findings obtained for other ADCs, such as the Her-2-targeting ADC trastuzumab-deruxtecan within DESTINY-PanTumor02 Phase II ascopubs.org/doi/abs/10.120… @JCO_ASCO & aacrjournals.org/clincancerres/… @AACR @CCR_AACR ➡️Future biomarker research should be performed to correlate NECTIN4 expression with EV response across entities! @Markuseckstein3 ➡️Urgently needed for ADC precision oncology! @OncoAlert @PTarantinoMD @urotoday @Uroweb @imedverse @drenriquegrande (# 4046)

Congratulations to the amazing @skopetz for his @AACR Waun Ki Hong Award. Eye opening listening to his presentation on Adaptive Resistance in BRAF- and KRAS-mutated #colorectalcancer #crcsm #AACR24 #AACRSSP @MDAndersonNews

AR-PROTAC BMS-986365 is a potent & rapid AR degrader with enzalutamide-like antagonist potency, low AR agonism, weak activity against AR L702H, claimed to be selective against CRBN neosubstrates (data not shown) & allows to overcome AR feedback up-regulation. #AACR24 #TPD

The #OncoAlertTOPtweet at Day 1 of #EAU24 Post By @OncoAlert 🚨GU Faculty @tompowles1 🇬🇧 Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24. Do we need to give adjuvant therapy to those as such low risk?

It‘been a while, but 🎉🔬 The 17th episode is out. The last entity we tackled was the „incarnation“ of hot/inflamed urothelial carcinomas🔥🔥🔥🔥 But what do you know about PD-L1 testing ? Today @MattGalsky presented important data of CheckMate274 at #EAU24. PD-L1 positive patients benefit significantly from adjuvant Nivolumav treatment. 👉 In Europe adjuvant Nivolumab is only approved for PD-L1 positive patients. 👉 PD-L1 testing is thus important and its importance might increase with current neoadjuvant studies reading out soon! But what does PD-L1 positive mean? Read below in following posts 👇 @AmerUrological, @Uroweb, @ASCO, @PathSoc. #Uropathology #urothelial #cancer #MedicalInnovation @NEJM @JAMANetwork @JAMA_current @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper #pathtwitter @brookmans76 @PGrivasMDPhD @DrYukselUrun @shilpaonc @drenriquegrande @amerseburger

So insightful! Never understood it as well until this explanation! Worth reading if you too have been stumped by the lack of consistency of clinical data when you group it together.

@Markuseckstein3 @EUplatinum @niklas_kluemper Congrats!

Really honored that our paper has been selected as best translational paper published @EUplatinum #EAU24 ☺️. Highlights the importance of assessing biomarkers in the right tissue specimen especially for immune biomarkers 🎯. Thanks so much to all contributors @niklas_kluemper @HolzelMichael @ChrisBolenz @roghmann @hartmann_arndt @urotoday @OncoAlert @imedverse and of course to those that are not on X. 👉 sciencedirect.com/science/articl…

@bilenma @WinshipAtEmory Congrats!

Feeling incredibly grateful for all the support! Excited to take on the role of inaugural professorship at Winship and work with our outstanding multi-D team. Let's keep pushing boundaries and making strides together! 🙏 #Grateful @WinshipAtEmory

This trial will answer several important questions- do we need to escalate therapy to get better outcomes in the highest risk patients, and can we de-escalate in those who are lower risk. @MattGalsky @apolo_andrea @tompowles1 @sonpavde @TiansterZhang

@Markuseckstein3 @EKFStiftung Congrats Markus!

Really honored to receive this funding by @EKFStiftung ! It is a great opportunity to push our group‘s effort to develop novel (immunotherapy) approaches for #urothelial #cancer patients!

We report for the 1st time therole of tumor fraction in ctDNA in pts w/ mUC in RW @FoundationATCG 👉 ass. w/ clinico-path features & rwPFS 👉prognostic biomarker 👉may help personalize tx 👉prospective trials needed @myESMO @ElsevierNews @CleClinicMD protect-us.mimecast.com/s/jGBqCR6nEvtn…